March 2006

Foreword: Anti-angiogenic therapy: Maximizing therapeutic gain

Adam P. Dicker

Thomas Jefferson University

Let us know how access to this document benefits you

Follow this and additional works at: http://jdc.jefferson.edu/radoncfp

Part of the Radiology Commons

Recommended Citation


http://jdc.jefferson.edu/radoncfp/3
FOREWORD: ANTI-ANGIOGENIC THERAPY: MAXIMIZING THERAPEUTIC GAIN

Adam P. Dicker, MD, PHD

Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA


The symposium brought together a diverse group of clinicians and basic scientists, leading experts in the field, to foster the development of innovative research in multicenter cooperative group projects. The topics covered were the following: role of angiogenesis in normal tissue biology and cancer cell biology, mechanism of action in tumor-growth inhibition of selective anti-angiogenic inhibitors, effects of anti-angiogenic inhibitors on preclinical tumor models alone and in combination with cytotoxic chemotherapy and radiation therapy, issues regarding clinical trial design using novel agents, and the results of clinical trials using inhibitors of angiogenesis alone or in combination with radiation or chemotherapy.

I would like to acknowledge the advice and support of Dr. Walter Curran, Jr., chairman of the RTOG, and Tom Wudarski and Sharon Hartson Stine, who provided logistical support and help with visual materials. I would also like to acknowledge the helpful feedback and counsel of members of the Translational Research Program, including Drs. Luka Milas and Paul Okunieff.

Reprint requests to: Adam P. Dicker, M.D., Ph.D., Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19107-5097. Tel: (215) 955-6527; Fax: (215) 955-0412; E-mail: adam.dicker@mail.tju.edu